Scarica l'app Stockscreener
18.57
3.88%
-0.75
Dopo l'orario di chiusura:
18.62
0.05
+0.27%
Legend Biotech Corp Adr Borsa (LEGN) Ultime notizie
Legend Biotech launches grant program for myeloma research - Investing.com
Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright reiterates Legend Biotech stock rating on durability data - Investing.com
ETFs Investing in Legend Biotech Corp. Sponsored ADR Stocks - TradingView
Preferred dividends of Legend Biotech Corp. Sponsored ADR – HAN:9LB - TradingView
Legend Biotech Corp. Sponsored ADR Statistics – HAN:9LB - TradingView
Form 4 Legend Biotech Corp For: 29 September - Investing.com India
Form 144 Legend Biotech Corp For: 27 September By Investing.com - Investing.com Nigeria
Form 144 Legend Biotech Corp For: 27 September - Investing.com India
Legend Biotech reports 5-year CARVYKTI data in myeloma patients - Investing.com
Legend Biotech CFO Carlos E. Santos Reports Share Acquisition and Sale on September 21, 2026 - Kalkine Media
Form 4 Legend Biotech Corp For: 23 September By Investing.com - Investing.com India
Legend Biotech CFO Carlos Santos sells $49,630 in shares - Investing.com
Form 144 Legend Biotech Corp For: 22 September By Investing.com - Investing.com India
Legend Biotech CEO Ingrid Zhang Granted 1.13 Million RSUs with Three-Year Vesting - Kalkine Media
Data on five-year remission with a myeloma treatment will be presented in Scotland - Stock Titan
H.C. Wainwright reiterates Legend Biotech stock rating at buy - investing.com
Legend Biotech (LEGN) Institutional Ownership 2026 - MarketBeat
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock at $65 - Investing.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
RBC cuts Legend Biotech stock price target to $59 on model updates - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Stock Price Up 6.8%Here's Why - MarketBeat
Q4 EPS Estimates for Legend Biotech Cut by HC Wainwright - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com - Investing.com South Africa
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
LEGNLegend Biotech Corp ADR Options - Finviz
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):